Cefazolin - Celerity Pharmaceuticals

Drug Profile

Cefazolin - Celerity Pharmaceuticals

Alternative Names: Cefazolin in plastic container - Baxter/Celerity; Cefazolin injection in GALAXY container

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celerity Pharmaceuticals
  • Developer Baxter Healthcare Corporation; Celerity Pharmaceuticals
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Oct 2015 Registered for Bacterial infections (Prevention) in USA (IV)
  • 14 Aug 2015 Celerity Pharmaceuticals enters into a collaboration with Baxter Healthcare for the development of Cefazolin injection in GALAXY container before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top